Morgan Stanley analyst Matthew Harrison raised the firm’s price target on Gilead to $85 from $81 and keeps an Equal Weight rating on the shares. The firm issued its biotechnology Q1 sector preview, stating that broadly for the group it does not "expect many surprises" given recently issued guidance. The firm sees investor focus being mainly on Q2 catalysts in the space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD:
- InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA
- Arcellx price target raised to $39 from $35 at SVB Securities
- NuCana Craters after EU Patent Problems
- Gilead, Pionyr Immunotherapeutics change 2020 exclusive option agreements
- Kite announces primary OS analysis results of Phase 3 ZUMA-7 study